» Articles » PMID: 3260839

Interleukin 2 Inhibitor in Synovial Fluid

Overview
Date 1988 Apr 1
PMID 3260839
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Since evidence for the presence of IL-2 activity in rheumatoid synovial fluid is conflicting, we have assayed IL-2 activity in synovial fluid from patients with rheumatoid arthritis (RA) and other articular diseases (OAD). Using the IL-2-dependent murine T cell line CTLL, IL-2 activity was not demonstrable in synovial fluid tested at concentrations ranging from 50% to 0.02%. There was an inhibitory effect on IL-2 activity in the bioassay of synovial fluid from 16 of the 22 patients with RA and 15 of the 16 with OAD. This inhibitory activity was heat-labile, precipitable by ammonium sulphate, reversible with excess IL-2 and was not significantly altered by preincubation of synovial fluid with CTLL. The mean inhibitory activity of synovial fluid from patients with RA was significantly reduced in comparison with that of synovial fluid from patients with OAD. Sera also had an inhibitory effect on IL-2 activity; however sera from patients with RA were less inhibitory than control sera but were more inhibitory than sera from patients with systemic lupus erythematosus. The deficiency in synovial fluid of an inhibitor of IL-2 activity may be relevant to the pathogenesis of RA.

Citing Articles

Expression and function of CD5 and CD28 in patients with rheumatoid arthritis.

Verwilghen J, Corrigall V, Pope R, Rodrigues R, Panayi G Immunology. 1993; 80(1):96-102.

PMID: 7503950 PMC: 1422109.


Premises for immune interventional therapy in rheumatoid arthritis.

Mackay I, Rowley M Postgrad Med J. 1988; 64(753):522-30.

PMID: 3074285 PMC: 2428904. DOI: 10.1136/pgmj.64.753.522.


The role of cytokines in the pathogenesis of rheumatoid arthritis.

Lipsky P, Davis L, Cush J Springer Semin Immunopathol. 1989; 11(2):123-62.

PMID: 2479111 DOI: 10.1007/BF00197186.


Interleukin 2 (IL 2) inhibitor in rheumatoid synovial fluid: correlation with prognosis and soluble IL 2 receptor levels.

Miossec P, Elhamiani M, Chichehian B, DAngeac A, Sany J, Hirn M J Clin Immunol. 1990; 10(2):115-20.

PMID: 2338453 DOI: 10.1007/BF00918193.


Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect.

Hain N, Alsalameh S, Bertling W, Kalden J, Burmester G Rheumatol Int. 1990; 10(5):203-10.

PMID: 2075373 DOI: 10.1007/BF02274834.


References
1.
Lelchuk R, Schmidt J, Hodson K, ASTON R, Liew F . Is there an interleukin 2 inhibitor in human serum?. Cell Immunol. 1987; 104(1):126-33. DOI: 10.1016/0008-8749(87)90013-x. View

2.
Djeu J, Kasahara T, Balow J, Tsokos G . Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol. 1986; 65(2):279-85. PMC: 1542294. View

3.
Miossec P, KASHIWADO T, ZIFF M . Inhibitor of interleukin-2 in rheumatoid synovial fluid. Arthritis Rheum. 1987; 30(2):121-9. DOI: 10.1002/art.1780300201. View

4.
Emery P, GENTRY K, Mackay I, Muirden K, Rowley M . Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1987; 30(8):849-56. DOI: 10.1002/art.1780300802. View

5.
ROPES M, BENNETT G, COBB S, JACOX R, JESSAR R . 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958; 9(4):175-6. View